TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01166438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Botox A®)
Description: A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 5mg
Description: Oral Solifenacin 5mg once a day for up to 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 10mg
Description: Oral Solifenacin 10mg once a day for up to 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium chloride
Description: Oral Trospium chloride XR 60mg once a day for up to 2 months
Study: NCT00373672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil (Nuvigil)
Description: armodafinil (Nuvigil)150 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical in appearance to active comparator
Study: NCT03681678

Intervention type: DEVICE
Intervention: fCO2 Laser Therapy Group
Description: Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
Study: NCT04096638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion
Study: NCT01738620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological counseling
Study: NCT04096638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion
Study: NCT01738620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevention of sleep disorders in ICU

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevention of sleep disorders in ICU
Study: NCT00420199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
Study: NCT03764839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Digital Behavioral Pian Medicine My Surgical Success
Description: The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success.
Study: NCT03286751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT01649830

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
Study: NCT04244656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX120
Description: CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study: NCT00695630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 2 mL, 0.2 mg SM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL sterile saline SM
Study: NCT01330316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks
Study: NCT03088592

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep Brain Stimulation
Description: Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
Study: NCT00338598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine, 0.8 gr per kg given in two daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00003835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03769402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric acid ph1, 50% concentration solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Test
Description: Control group, xenograft was used to fill infrabony defects without treating bone surface
Study: NCT00595504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
Study: NCT03015506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Study: NCT04096638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680 mg every 4 weeks
Study: NCT00169559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW590735
Description: 1µg to 20µg daily doses of GW590735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW590735
Description: 1µg to 20µg daily doses of GW590735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate
Description: Marketed Drug
Study: NCT03859258

Intervention type: DEVICE
Intervention: Transvaginal sonography
Description: Niche is assessed using TVS, SIS (cases only) and office hysteroscopy

Intervention type: DEVICE
Intervention: Transvaginal sonography
Description: Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
Study: NCT04367558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, in-office, RF reduction of the affected area
Description: Usage of RF needle to treat one or more of the affected areas
Study: NCT01981525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
Study: NCT01538472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y Zevalin
Description: Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In Zevalin
Description: Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 by vein on Day -6.
Study: NCT04096638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680 mg every 4 weeks
Study: NCT01538472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP -16
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Autologous stem cell infusion on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
Study: NCT01291784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody to TGF-beta
Description: starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
Study: NCT02992925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-High（Combined Vaccine）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-High（Combined Vaccine）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-Low（Combined Vaccine）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-Low（Combined Vaccine）

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-IPV
Study: NCT03074227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic faecal transplantation
Description: Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autologous faecal transplantation
Description: Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
Study: NCT00948974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
Study: NCT01509417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ad lib feedings after pyloromyotomy
Description: ad lib feedings after pyloromyotomy
Study: NCT03996057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1000 MG
Description: Discussed in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Description: Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
Study: NCT01509417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLAP diet after pyloromyotomy
Description: FLAP diet after pyloromyotomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FLAP diet after pyloromyotomy
Description: FLAP diet after pyloromyotomy
Study: NCT03996057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal estrogen
Description: Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-mannose
Description: Powder or tablet, depending on what patient is already using.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-mannose
Description: Powder or tablet, depending on what patient is already using.
Study: NCT04272359

Intervention type: DRUG
Intervention: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.
Study: NCT02382406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
Study: NCT02274389

Intervention type: DRUG
Intervention: No Intervention
Description: This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
Study: NCT02505854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
Study: NCT01972529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (lower baseline platelet count)
Description: 60 mg avatrombopag (3 x 20 mg tablets)
Study: NCT02505854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiotic
Description: Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
Study: NCT04551885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT02382406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (Phase I)
Description: MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (Phase II)
Description: MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Study: NCT02350127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
Study: NCT01972529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (lower baseline platelet count)
Description: 60 mg placebo (3 x 20 mg matching placebo tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (higher baseline platelet count)
Description: 40 mg avatrombopag (2 x 20 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (higher baseline platelet count)
Description: 40 mg placebo (2 x 20 mg matching placebo tablets)
Study: NCT00783731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose midazolam
Study: NCT01520818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administered subcutaneously (s.c., under the skin), twice a day
Study: NCT00546780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tanespimycin
Description: Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
Study: NCT01208948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,2 dithiolane 3 valeric acid
Description: 600 mg alpha lipoic acid per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1,2 dithiolane 3 valeric acid
Description: 600 mg alpha lipoic acid per day